With the development of proviral HIV-1 DNA drug resistance testing, clinicians can now incorporate this novel drug resistance technology to identify antiretroviral drugs that are active against the virus. This technology is needed because improvements in HIV-1 antiretroviral (ARV) drugs have led to therapeutic advances resulting in more patients with complete and sustained suppression of virus replication. In this setting of sustained viral suppression, HIV-1 proviral DNA drug resistance testing can be a useful tool to guide treatment adjustments or regimen switches that may be necessary due to adverse events, regimen intolerance or drug-drug interactions. Regimen modification should be made cautiously because archived drug resistant viruses harbored within latently infected cells have the opportunity to emerge under appropriate selective drug pressure.
Therefore, it is critical to review the full ARV treatment history of patients prior to selecting a new treatment regimen. Information gained from HIV-1 DNA resistance testing, such as the GenoSure Archive assay, may be used in combination with historical plasma RNA resistance test results to guide regimen switching in the setting of viral suppression. This testing may also provide added information regarding archived drug resistance when prior resistance test results are unavailable or incomplete. Although originally intended for those patients who are virologically suppressed, the clinical application of proviral HIV-1 DNA resistance testing may extend to other patient scenarios.
Register for this webinar to hear experts discuss the fundamentals of proviral DNA resistance testing, address common questions and provide insight into its application and usefulness in the clinical setting.
Charles Walworth, MD - Associate VP, Medical Affairs and Education, Labcorp/Monogram Biosciences
Dr. Walworth completed his undergraduate work and medical school at Georgetown University. His interest in working in the field of HIV was triggered while working in a refugee camp on the Thai-Cambodian border, during which time the first five cases of AIDS were reported at Bangkok General Hospital. He subsequently completed a fellowship in infectious diseases at the National Institutes of Health and served as the Clinical Trials Physician in the NIAID Clinical Trials Unit. He later entered private practice in Orange County, CA where he built a very large HIV practice, conducted numerous clinical trials, served on speakers’ bureaus and advisory boards for multiple pharmaceutical companies, and worked closely with AIDS service organizations. In 2008, he joined Monogram Biosciences in South San Francisco, CA, initially as Director of Global Medical Affairs. He is now the Associate Vice President of Medical Affairs and Education at Monogram Biosciences/Labcorp.Message Presenter
Dusica Curanovic, PhD - Medical Science Liaison, Labcorp/Monogram Biosciences
Dr. Curanovic is a trained virologist with a PhD in Molecular Biology from Princeton University. She conducted academic research at Weill Cornell Medical College and UNC Chapel Hill, has published primary research and book chapters, and has lectured on a variety of topics in virology. Prior to joining Monogram, Dr. Curanovic reported clinical trial outcomes, and planned and executed data dissemination strategies for HIV therapeutics. At Monogram, she has been spearheading the efforts in biomarker development for HIV-Associated Neurocognitive Disorder, and other HIV-associated neurologic testing. She is the Medical Science Liaison for the Southeast Region.Message Presenter
Sharon Martens, MN - Medical Science Liaison, Labcorp/Monogram Biosciences
Sharon has a Bachelor of Science in Nursing from Creighton University. She received a Master’s Degree in Nursing from the University of Washington as a Family Nurse Practitioner where she was inducted into Sigma Theta Tau National Honor Society. Sharon is a very experienced clinician and has 22 years’ experience as an HIV specialist at the University of Washington’s Harborview Medical Center HIV specialty clinic. She has also worked as a research coordinator and study clinician for the Pediatric AIDS Clinical Trials Group. Since joining Monogram, Sharon has been the Medical Science Liaison for the Western United States.Message Presenter
Milka Rodriguez, PhD - Medical Science Liaison, Labcorp/Monogram Biosciences
Dr. Rodriguez earned her PhD in Infectious Diseases and Microbiology from University of Pittsburgh, Graduate School of Public Health and completed postdoctoral fellowships at Weill Cornell Medical College and Albert Einstein College of Medicine. Prior to joining Labcorp in 2015, Dr. Rodriguez was Assistant Director of Epigenetic Services at Epigentek Group, Inc. At Labcorp, she works closely with the Medical Affairs team on various research and development projects to bring innovative diagnostic tools for HIV disease management to market. Dr. Rodriguez is the Medical Science Liaison for the Northeast Region.Message Presenter
Who Should Attend?
Healthcare professionals involved in the care of people living with HIV:
- Primary care physicians
- Infectious diseases specialists
- Internal medicine clinicians
- Nurse practitioners/physician assistants
- Clinical laboratory professionals
What You Will Learn
Webinar topics will include:
- Understanding the difference between proviral DNA and standard plasma RNA virus drug resistance testing
- Understanding the limitations of HIV-1 drug resistance testing
- Applying DHHS HIV-1 proviral DNA resistance testing considerations to clinical practice
- Applying proviral HIV-1 DNA resistance testing in the clinical management of people living with HIV
Monogram Biosciences, a wholly-owned subsidiary of Labcorp, is a leader in developing and commercializing innovative, diagnostic products to help guide and improve treatment of human immunodeficiency virus (HIV), hepatitis C virus (HCV), SARS-CoV-2, and other diseases. Monogram’s services enable health care providers to optimize treatment regimens for their patients. We also support pharmaceutical companies in developing new and improved antiviral therapeutics and vaccines and targeted cancer therapeutics.
Monogram Bioscience, founded in San Francisco in 1995, is a leading commercial company that performs HIV phenotypic testing. Our clinical reference lab is fully CAP and CLIA accredited.
Monogram provides testing for clinical patient management and drug/vaccine development, and supports clinical trials directly and as part of the Covance Drug Development team. To date, Monogram scientists have published more than 200 articles in peer-reviewed journals.